Ministry of Health

Administration of Pfizer-BioNTech COVID-19 Vaccine


Highlights of changes

- Additional information on Polyethylene glycol (page 4)
- Minor formatting updates for consistency with other guidance
- Reference and hyperlink to “Vaccination Recommendations for Special Populations” guidance document

This guidance provides basic information only. It is not intended to take the place of medical advice, diagnosis or treatment, legal advice or legal requirements.

In the event of any conflict between this guidance document and any applicable emergency orders, or directives issued by the Minister of Health, Minister of Long-Term Care, or the Chief Medical Officer of Health (CMOH), the order or directive prevails.

- Please check the Ministry of Health (MOH) COVID-19 website regularly for updates to this document.

What is COVID-19?

COVID-19 is a novel coronavirus disease 2019 that is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Anyone can be infected with SARS-CoV-2 (COVID-19). However, some populations are at increased risk of exposure to the virus (e.g., due to living or work settings), and some populations are at increased risk of severe disease and death due to biological (e.g., advanced age, pre-existing medical conditions) and social (e.g., low socioeconomic status, belonging to a racialized population) factors.

Additional information about the Pfizer-BioNTech COVID-19 Vaccine can be found in the product monograph.
General Clinic Precautions

All staff working in the clinic must take appropriate infection prevention and control measures, including donning appropriate personal protective equipment (PPE) when interacting with clients as they move through the immunization clinic and when responding to any adverse events following immunization.

The Vaccine

<table>
<thead>
<tr>
<th>Pfizer-BioNTech COVID-19 Vaccine</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Type of vaccine</strong></td>
</tr>
<tr>
<td><strong>Date of authorization in Canada</strong></td>
</tr>
<tr>
<td><strong>Authorized ages for use</strong></td>
</tr>
<tr>
<td><strong>Dose</strong></td>
</tr>
<tr>
<td><strong>Schedule</strong></td>
</tr>
<tr>
<td><strong>Booster doses</strong></td>
</tr>
<tr>
<td><strong>Route of administration</strong></td>
</tr>
<tr>
<td><strong>Nature of the antigen</strong></td>
</tr>
<tr>
<td><strong>Adjuvant (if present)</strong></td>
</tr>
<tr>
<td>Storage requirements</td>
</tr>
<tr>
<td>--------------------------------------</td>
</tr>
<tr>
<td><strong>Frozen vials prior to use</strong></td>
</tr>
<tr>
<td><strong>Vials prior to dilution</strong></td>
</tr>
<tr>
<td><strong>Vials after dilution</strong></td>
</tr>
<tr>
<td><strong>Formats available</strong></td>
</tr>
<tr>
<td><strong>Usage limit post-dilution</strong></td>
</tr>
<tr>
<td><strong>Drug Interactions</strong></td>
</tr>
</tbody>
</table>
Who Should Not Receive the Vaccine

The Pfizer-BioNTech COVID-19 vaccine is contraindicated in:

- Individuals who have ever had a severe allergic reaction (i.e. anaphylaxis) to a previous dose of an mRNA vaccine or to any of its components (including polyethylene glycol (PEG) and/or polysorbate) or its container, should not get either mRNA COVID-19 vaccine. PEG can rarely cause allergic reactions and is found in products such as medications, bowel preparation products for colonoscopy, laxatives, cough syrups, cosmetics, skin creams, medical products used on the skin and during operations, toothpaste, contact lenses and contact lens solution. PEG also can be found in foods or drinks but is not known to cause allergic reactions from foods or drinks.

- Vaccination should be deferred in symptomatic individuals with confirmed or suspected SARS-CoV-2 infection, or those with symptoms of COVID-19.

- As a precautionary measure and in light of the need to be able to monitor for COVID-19 vaccine adverse events without potential confounding from symptoms of COVID-19 or other co-existing illness, it would be prudent to wait for all symptoms of acute illness to completely resolve.

- Individuals who have received another vaccine (not a COVID-19 vaccine) in the past 14 days.

- **Individuals under the age of 16**: The safety and efficacy in children under 16 years of age have not yet been established. The manufacturer plans to conduct clinical trials in children.

**Considerations for other patient groups**

- Guidance for special populations, including for example breastfeeding or pregnant individuals, individuals with allergies, individuals with autoimmune conditions, or individuals who are immunocompromised due to disease or treatment, is available in the [Vaccination Recommendations for Special Populations](#) guidance document.

**Precautions during vaccination should be taken for:**

- Patients who have a bleeding problem, bruise easily or use a blood-thinning medicine should receive the vaccine. Individuals receiving long-term anticoagulation with either warfarin or heparin are not considered to be at higher risk of bleeding complications following immunization and may be safely
immunized through the intramuscular route as recommended, without discontinuation of their anticoagulation therapy.
  - There is some evidence to suggest that intramuscular administration may be safer when given with a small gauge needle (23 gauge or smaller) and when firm pressure is applied to the injection site for 5 to 10 minutes
- Individuals with a history of severe allergic reactions (i.e. anaphylaxis) not related to vaccines or injectable medications—such as allergies to food, pet, venom, environmental, or latex, etc. should be offered the COVID-19 vaccines.
  - An extended period of observation post-vaccination of 30 minutes is recommended for these groups
- For more detailed recommendations on people with allergies, please consult the Vaccination Recommendations for Special Populations guidance document.

## Side effects

The Pfizer-BioNTech COVID-19 vaccine, like other medicines and vaccines can cause side effects, although not everyone gets them. The most common side effects of receiving the Pfizer-BioNTech COVID-19 vaccine are mild and include injection site pain, swelling or redness.

Other side effects that have been reported include headache, fatigue, muscle pain, chills, joint pain, fever and enlarged lymph nodes. Most of these side effects experienced were mild to moderate and on average did not last longer than three days. Please see the product monograph for a complete list of reported side effects/ adverse reactions.

<table>
<thead>
<tr>
<th>Very common side effects</th>
<th>May affect more than 1 in 10 people</th>
<th>• Pain at injection site</th>
<th>• Chills</th>
<th>• Fatigue</th>
<th>• Headache</th>
<th>• Muscle pain</th>
<th>• Joint pain</th>
<th>• Fever</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uncommon side effects</td>
<td>May affect up to 1 in 100 people</td>
<td>Enlarged lymph nodes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Adverse Events Following Immunization

What information should be provided to individuals related to potential adverse events following immunization (AEFIs) with the Pfizer-BioNTech COVID-19 vaccine?

As per s.38 of the Health Protection and Promotion Act, those administering vaccines should ensure that the vaccine recipients or their parents/guardians are advised to immediately call their doctor/nurse practitioner or go to the nearest hospital emergency department if they develop a reaction that could be related to the vaccine, particularly any of the following:

- Hives
- Swelling of the mouth and throat
- Trouble breathing, hoarseness or wheezing
- High fever (over 40°C or 104°F)
- Convulsions (seizures)
- Other serious reactions

Health care providers (e.g., physicians, nurses and pharmacists) are required by law (i.e., Health Protection and Promotion Act, s. 38) to report AEFIs. Reports should be made using the Ontario AEFI Reporting Form and sent to the local public health unit.

The Ontario Ministry of Health in collaboration with Public Health Ontario monitors reports of adverse events after immunization. This monitoring is done in collaboration with the Public Health Agency of Canada and Health Canada.

The Brighton Collaboration has developed a list of Adverse Events of Special Interests.

Point-of-care Guidance

- As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of this vaccine.
- The vaccine is administered through an intramuscular injection into the upper arm (deltoid muscle).
- In order to be fully effective in preventing SARS-CoV2 infection, the vaccine must be administered twice: a single dose of the vaccine is administered followed by a second single dose 21 days later.
○ A minimum of 19 days between the first and second dose with a recommended interval 21-28 days.
○ If administration of the second dose of the vaccine is delayed, it should be administered as soon as possible.

• In general, regardless of the time between doses, interruption of a vaccine series does not require restarting the series as delays between doses do not result in a reduction in final antibody concentrations for most multi-dose products. However, maximum protection may not be attained until the complete vaccine series has been administered.
• The vaccine series must be completed with the same COVID-19 vaccine product.
• Do not mix the Pfizer-BioNTech COVID-19 vaccine with other vaccines/products in the same syringe.
• Pfizer-BioNTech COVID-19 vaccine should not be given simultaneously with other live or inactivated vaccines.

Vaccine Preparation:

Additional information on vaccine preparation can be found in the product monograph.

• The Pfizer-BioNTech COVID-19 vaccine multiple dose vial contains a frozen suspension that does not contain preservative and must be thawed and diluted prior to administration.
• Vials may be thawed in the refrigerator (+2°C to +8°C) for up to 5 days, or at room temperature (up to +25°C) and used within 6 hours.
• Prior to dilution, the thawed suspension may contain white to off-white opaque amorphous particles. Before dilution, the vial must be inverted gently 10 times to mix the vaccine. Do not shake. The contents of the vial must be diluted with 1.8 mL of sterile 0.9% Sodium Chloride Injection, USP.
• The vial containing the Pfizer-BioNTech COVID-19 vaccine should be gently inverted 10 times to mix. Do not shake.
• It is acceptable to obtain 6 doses per vial if possible (which may be possible as the volume in the vial is 2.25 ml after dilution). The following is recommended:
  o Ensure the correct amount of diluent is added to the vial (1.8 ml)
  o Draw up the full dose (0.3 ml)
  o Do NOT mix leftovers from other vials to make up an additional dose. If you can’t get a full 6th dose from the vial, discard the remainder (i.e., if you tried to get the 6th dose into a syringe and there wasn’t enough for it, discard that syringe).
• After dilution, the vaccine will be an off-white suspension. Inspect vial to confirm there are no particulates and no discolouration is observed.
• The time and date of dilution must be recorded on the vial label and the vial must be stored between +2° C to +25° C. Any unused vaccine must be discarded 6 hours after dilution.
• Strict adherence to aseptic techniques must be followed.

Vaccine Administration:

• It is important the proper sized syringes (to ensure the correct volume is accurately drawn up) and safety engineered needles are used when administering the vaccine
• Visually inspect each dose in the dosing syringe prior to administration. The diluted vaccine will be an off-white suspension.
• During the visual inspection:
  o Verify the final dosing volume of 0.3 mL, and
  o Confirm there are no particulates and that no discolouration is observed.
• If the visual inspection fails, do not administer the vaccine.
• Administer Pfizer-BioNTech COVID-19 Vaccine intramuscularly in the deltoid muscle.
• Do not inject the vaccine intravascularly, subcutaneously or intradermally.

All clients should be reminded to continue to practice recommended public health measures for prevention and control of COVID-19 infection and transmission regardless of receipt of COVID-19 vaccine.

Storage, Stability and Disposal

Frozen Vials Prior to Use

• Cartons of Pfizer-BioNTech COVID-19 Vaccine multiple dose vials (after dilution each vial contains 5 doses of 0.3 mL) arrive in thermal containers with dry ice.
  o To ensure all appropriate safeguards are in place, refer to the Dry Ice Safety Data Sheet and the Pfizer-BioNTechCOVID-19 Vaccine Storage and Handling Reference Guide provided.
• Appropriate PPE must be worn when handling the vaccines.
• Once received, remove the vial cartons immediately from the thermal container and store in the freezer between -80°C to -60°C.
- Vials must be kept frozen between -80°C to -60°C and protected from light, in the original cartons, until ready to use.
- If an ultra-low temperature freezer is not available, the thermal container in which the Pfizer-BioNTech COVID-19 Vaccine arrives may be used as temporary storage when consistently refilled to the top of the container with dry ice.
  - Refer to the re-icing guidelines packed in the original thermal container for instructions regarding the use of the thermal container for temporary storage.
  - The thermal container maintains a temperature range of -90°C to -60°C. Storage within this temperature range is not considered an excursion from the recommended storage condition.

**Thawed Vials Prior to Dilution**
- Prior to dilution, multiple dose vials of Pfizer-BioNTech COVID-19 Vaccine may be thawed and stored in the refrigerator between +2°C to +8°C.
  - A carton of 25 vials or 195 vials may take up to 2 or 3 hours to thaw in the refrigerator, respectively, whereas a fewer number of vials will thaw in less time.
  - Vials may be stored in the refrigerator for up to 5 days (120 hours).
- Frozen vials may also be thawed at room temperature up to +25°C.
  - Prior to dilution, the multiple dose vial may be stored at room temperature for no more than 2 hours.
- During storage, minimize exposure to room light, and avoid exposure to direct sunlight and ultraviolet light.
- Thawed vials can be handled in room light conditions. **Do not refreeze thawed vials.**

**Vials After Dilution**
- After dilution, multiple dose vials of Pfizer-BioNTech COVID-19 Vaccine must be stored between +2°C to +25°C and **used within 6 hours from the time of dilution**.
- Any vaccine remaining in vials must be discarded after 6 hours.
- During storage, minimize exposure to room light, and avoid exposure to direct sunlight and ultraviolet light.
- After dilution, the vaccine vials can be handled in room light conditions.
- **Do not freeze. If the vaccine is frozen, it must be discarded.**